Synergistic transcription factors to induce high resistance transendothelial barrier

Patent metadata

Field	Value
Publication number	US-2021222122-A1
Application number	US-202117226974-A
Country	US
Kind code	A1
Filing date	Apr 9, 2021
Priority date	Oct 19, 2018
Publication date	Jul 22, 2021
Grant date	—

Abstract

This application relates to transcription factors capable of increasing transendothelial barrier integrity. Moreover, this application relates to the use of vectors encoding such transcription factors and cells comprising such vectors.

First claim

1 . A method for producing cells capable of establishing high transendothelial electrical resistance (TEER), comprising the step of contacting the cells with at least one transcription factor, wherein a confluent monolayer of the cells establishes higher transendothelial electric resistance compared to a confluent monolayer of cells not contacted with the at least one transcription factor.

2 . The method of claim 1 , wherein the at least one transcription factor is individually selected from the group consisting of TAL1, SOX18, FOXF2, SOX7, FOXC1, ETS1, KLF11, LMO2, and LEF1.

3 . The method of any one of claim 1 or 2 , wherein the at least one transcription factor is selected from the group consisting of ETS1, SOX18 and SOX7.

4 . The method of any one of claims 1 to 3 , wherein the transcription factors are i) ETS1, SOX18, SOX7 and TAL1; or (ii) ETS1, SOX18, SOX7 and LEF1.

5 . The method of any one of claims 1 to 4 , wherein isolated nucleic acids encoding the at least one transcription factor are introduced into the cell.

6 . The method of claim 5 , wherein the isolated nucleic acids are comprised in at least one expression vector, in particular wherein the at least one expression vector is individually selected from the group consisting of a viral vector, a non-viral vector, and a plasmid vector.

7 . The method of any one of claim 1 to 6 , wherein the cell is an endothelial cell (EC).

8 . An expression vector comprising isolated nucleic acids encoding at least one transcription factor selected from the group consisting of TAL1, SOX18, FOXF2, SOX7, FOXC1, ETS1, KLF11, LMO2, and LEF1

9 . The expression vector of claim 8 , which is a viral vector, a non-viral vector, or a plasmid vector.

10 . The expression vector of any one of claim 8 or 9 , wherein the isolated nucleic acids encode the transcription factors ETS1, SOX18 and SOX7.

11 . The expression vector of any one of claims 8 to 10 , wherein the isolated nucleic acids encode the transcription factors (i) ETS1, SOX18, SOX7 and TAL1; or (ii) ETS1, SOX18, SOX7 and LEF1.

12 . A cell comprising one or more of the expression vectors of any one of claims 8 to 11 .

13 . The cell according to claim 12 , wherein the cell is a mammalian cell, in particular a human cell.

14 . The method according to any one of claim 1 to 7 , wherein the cell capable of establishing high TEER is used for identifying a drug candidate capable of i) increasing in vivo transendothelial barrier integrity (TBI) or ii) decreasing in vivo TBI of endothelial cells.

15 . The method according to claim 14 comprising the steps of:
(a) providing a monolayer of cells capable of establishing high TEER;
(b) contacting the cells with the drug candidate;
(c) measuring in vitro TEER before and after contacting the cells with the drug candidate, or measuring in vitro TEER of the cells contacted with the drug candidate and in parallel measuring in vitro TEER of cells not contacted with the drug candidate;
wherein (i) a higher in vitro TEER of the cells contacted with the drug candidate compared with the in vitro TEER of the cells not contacted with the drug candidate is indicative of a drug capable of increasing in vivo TBI of ECs, and (ii) a lower in vitro TEER of the cells contacted with the drug candidate compared with the in vitro TEER of the cells not contacted with the drug candidate is indicative of a drug capable of decreasing in vivo TBI of ECs.

16 . A method for identifying a drug candidate capable of i) increasing in vivo transendothelial barrier integrity (TBI) or ii) decreasing in vivo TBI of endothelial cells, the method comprising the steps of:
(a) providing a monolayer of the cells of any one of claim 12 or 13 ; (b) contacting the cells with the drug candidate; (c) measuring in vitro TEER before and after contacting the cells with the drug candidate, or measuring in vitro TEER of the cells contacted with the drug candidate and in parallel measuring in vitro TEER of cells not contacted with the drug candidate;
wherein (i) a higher in vitro TEER of the cells contacted with the drug candidate compared with the in vitro TEER of the cells not contacted with the drug candidate is indicative of a drug capable of increasing in vivo TBI of ECs, and (ii) a lower in vitro TEER of the cells contacted with the drug candidate compared with the in vitro TEER of the cells not contacted with the drug candidate is indicative of a drug capable of decreasing in vivo TBI of ECs.

Assignees

• Hoffmann La Roche

Inventors

• Cowan Chad A
• Meyer Claas Aiko
• Roudnicky Filip

Classifications

• C12N5/069 Primary

  Vascular Endothelial cells · CPC title

• C12N15/85

  for animal cells · CPC title

• C12N2501/60

  Transcription factors · CPC title

• C12N2510/00

  Genetically modified cells · CPC title